KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) EBT Margin (2017 - 2025)

Aquestive Therapeutics has reported EBT Margin over the past 9 years, most recently at 244.79% for Q4 2025.

  • Quarterly results put EBT Margin at 244.79% for Q4 2025, down 10096.0% from a year ago — trailing twelve months through Dec 2025 was 188.09% (down 11139.0% YoY), and the annual figure for FY2025 was 188.09%, down 11139.0%.
  • EBT Margin for Q4 2025 was 244.79% at Aquestive Therapeutics, down from 120.61% in the prior quarter.
  • Over the last five years, EBT Margin for AQST hit a ceiling of 72.46% in Q1 2023 and a floor of 618.35% in Q2 2021.
  • Median EBT Margin over the past 5 years was 112.59% (2021), compared with a mean of 143.42%.
  • Biggest five-year swings in EBT Margin: soared 41458bps in 2022 and later tumbled -17889bps in 2024.
  • Aquestive Therapeutics' EBT Margin stood at 261.28% in 2021, then surged by 56bps to 115.63% in 2022, then soared by 48bps to 60.65% in 2023, then plummeted by -137bps to 143.84% in 2024, then tumbled by -70bps to 244.79% in 2025.
  • The last three reported values for EBT Margin were 244.79% (Q4 2025), 120.61% (Q3 2025), and 135.44% (Q2 2025) per Business Quant data.